Log in

NASDAQ:MGTXMeiraGTx Stock Price, Forecast & News

$14.35
-0.04 (-0.28 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.09
Now: $14.35
$14.86
50-Day Range
$12.89
MA: $14.29
$15.97
52-Week Range
$8.82
Now: $14.35
$30.23
Volume111,733 shs
Average Volume101,924 shs
Market Capitalization$536.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.
Read More
MeiraGTx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
CUSIPN/A
CIKN/A
Phone646-860-7985

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.29 million
Book Value$5.22 per share

Profitability

Net Income$-54,750,000.00
Net Margins-313.70%

Miscellaneous

Employees68
Market Cap$536.12 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.

MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

How has MeiraGTx's stock been impacted by COVID-19 (Coronavirus)?

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MGTX shares have increased by 1.8% and is now trading at $14.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MeiraGTx?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MeiraGTx.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MeiraGTx.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings PLC (NASDAQ:MGTX) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.05. The firm earned $4.21 million during the quarter. MeiraGTx had a negative return on equity of 29.96% and a negative net margin of 313.70%. View MeiraGTx's earnings history.

What price target have analysts set for MGTX?

2 analysts have issued 1-year price targets for MeiraGTx's shares. Their forecasts range from $40.00 to $45.00. On average, they anticipate MeiraGTx's stock price to reach $42.50 in the next year. This suggests a possible upside of 196.2% from the stock's current price. View analysts' price targets for MeiraGTx.

What are Wall Street analysts saying about MeiraGTx stock?

Here are some recent quotes from research analysts about MeiraGTx stock:
  • 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (3/18/2020)
  • 2. Chardan Capital analysts commented, "We rate MeiraGTx Buy on the forward- looking approach Meira management has taken to develop one of the broadest pipelines in all of AAV-based GT, including one with both lower-risk IRD opportunities for early wins and with higher-risk large-market opportunities that could generate profound investment returns." (9/23/2019)

Has MeiraGTx been receiving favorable news coverage?

News coverage about MGTX stock has been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MeiraGTx earned a news impact score of -3.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutMeiraGTx.

Are investors shorting MeiraGTx?

MeiraGTx saw a decline in short interest in May. As of May 15th, there was short interest totaling 579,000 shares, a decline of 7.5% from the April 30th total of 626,000 shares. Based on an average daily trading volume, of 114,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 2.0% of the shares of the stock are short sold. View MeiraGTx's Current Options Chain.

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
  • Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
  • Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
  • Mr. Micah Zajic, VP of Corp. Devel.

When did MeiraGTx IPO?

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (9.59%), Johnson & Johnson Innovation JJDC Inc. (7.76%), BlackRock Inc. (3.29%), Prosight Management LP (1.52%), State Street Corp (0.96%) and Alyeska Investment Group L.P. (0.93%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk. View institutional ownership trends for MeiraGTx.

Which major investors are selling MeiraGTx stock?

MGTX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, Ensign Peak Advisors Inc, Victory Capital Management Inc., Victory Capital Management Inc., and SG Americas Securities LLC. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk. View insider buying and selling activity for MeiraGTx.

Which major investors are buying MeiraGTx stock?

MGTX stock was acquired by a variety of institutional investors in the last quarter, including Johnson & Johnson Innovation JJDC Inc., Orbimed Advisors LLC, Alps Advisors Inc., Rhenman & Partners Asset Management AB, Prosight Management LP, JPMorgan Chase & Co., Fort Sheridan Advisors LLC, and AQR Capital Management LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman. View insider buying and selling activity for MeiraGTx.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $14.35.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $536.12 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.

What is MeiraGTx's official website?

The official website for MeiraGTx is www.meiragtx.com.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.